Correlation Engine 2.0
Clear Search sequence regions


  • antimetabolites (2)
  • feet (1)
  • foot (9)
  • humans (1)
  • patients (2)
  • PSMC (5)
  • skin responses (1)
  • Sizes of these terms reflect their relevance to your search.

    This study sought to test the effectiveness of EVOSKIN®Palm and sole moisturizing cream (PSMC) in preventing and treating hand-foot syndrome (HFS) during capecitabine chemotherapy. Stage II/III colorectal cancer patients receiving capecitabine adjuvant chemotherapy were randomly allocated to receive either EVOSKINPSMC or physiological saline treatments for their hands and feet. Treatment was initiated along with adjuvant chemotherapy and continued till the end of chemotherapy. Participants' skin responses were evaluated every 3 weeks. During the study, 51 participants in the EVOSKIN PSMC group and 54 participants in the physiological saline group completed at least three cycles of capecitabine chemotherapy. The total incidence of HFS in the EVOSKIN PSMC group was lower than that in the physiological saline group (56.8% vs. 75.9%, P=0.006), as was the incidence of Grade 3/4 HFS (6.0% vs. 18.5%, P=0.011). The incidence of HFS became significant after 6weeks of chemotherapy. Further, the incidence of severe HFS was significant from as early as 3weeks after the commencement of chemotherapy despite the use of EVOSKIN PSMC to manage the condition. Notably, the incidence of Grade 1/2 HFS was not statistically significant between the two groups (26/51 vs. 32/54, 52.0% vs. 59.2%, P=0.194). The incidence of severe HFS among individuals using oral capecitabine can be reduced by the prophylactic treatment of EVOSKIN PSMC, this treatment is reasonable and acceptable for patients with capecitabine chemotherapy.

    Citation

    Weiqun Lu, Zhiliang Huang, Shicai Chen, Huizeng Lv, Xinqi Chen, Jian Lei, Chuanfeng Ke, Chuyuan Hong, Yisheng Wei, Rong Su, Rong Chen, Zheng Sun, Ping Yang, Xiaojun Tan, Haiying Liu. The effectiveness of EVOSKIN®Palm and sole moisturizing cream in treating capecitabine-associated hand-foot syndrome: a randomized double-blind clinical trial. Annals of palliative medicine. 2021 Mar;10(3):3009-3017

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 33849091

    View Full Text